Abstract

Haloperidol 0.5-mg/mL in SyrSpend SF pH4

Author(s): Allen Loyd V Jr

Issue: Sep/Oct 2021 - Volume 25, Number 5

Page(s): 417

Download in electronic PDF format for $75
  • Haloperidol 0.5-mg/mL in SyrSpend SF pH4 Page 1

Abstract

A formulation for preparing Haloperidol 0.5-mg/mL in SyrSpend SF pH4. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • haloperidol
  • formulation
  • oral suspension
  • antipsychotic agent
  • dyskinesis
  • antidyskinetic agent
  • Tourette syndrome
  • movement disorders
  • mood disorders
  • psychoses
  • schizophrenia
  • schizoaffective disorders
  • suicide
  • aggression
  • aggressive behavior
  • hallucinations

Related Categories

  • FORMULATIONS
  • MENTAL HEALTH
  • NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2021
Pg. 417
Haloperidol 0.5-mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48
Basics of Compounding for Disorders of the External Ear
Author(s): Allen Loyd V Jr
May/Jun 2010
Pg. 182-192
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2020
Pg. 229
Prednisolone 1 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr
Nov/Dec 2019
Pg. 487
Prednisolone Sodium Phosphate 1.4 mg/mL in SyrSpend SR pH4, Cherry Flavored
Author(s): Allen Loyd V Jr
Sep/Oct 2009
Pg. 386-389
Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Author(s): Williams LaVonn A, Fokken Dawn
Nov/Dec 2017
Pg. 493
Haloperidol 5-mg/mL Injection
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Jul/Aug 2011
Pg. 340
Methylprednisolone 4-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2019
Pg. 486
Gabapentin 50-mg/mL in SyrSpend SF Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Nov/Dec 2011
Pg. 504
Morphine 6-mg/mL, Haloperidol 0.5-mg/mL, and Hyoscine 6-mg/mL Infusion
Author(s): Allen Loyd V Jr
Jul/Aug 2011
Pg. 302-307
Treating Inner Ear Disorders with Intratympanic Drug Administration
Author(s): McElhiney Linda F
Jan/Feb 2020
Pg. 60
Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2018
Pg. 148
Lamotrigine 1-mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2012
Pg. 422
Haloperidol 50-mg/mL in Oil Injection
Author(s): Allen Loyd V Jr
Mar/Apr 1997
Pg. 87-89
Attention Deficit Hyperactivity Disorder
Author(s): Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 412
Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr